Edwards Lifesciences
This article was originally published in The Gray Sheet
Executive Summary
Next-generation Lifepath endovascular graft system for abdominal aortic aneurysms, which uses stronger "wireform" supports, gains CE mark approval for European marketing. In April 2000, Edwards suspended sales of a first-generation system outside the U.S., as well as clinical trials worldwide, following fractures in the wire scaffolding